Introduction
Cysteine (Cys), homocysteine (Hcy),a nd glutathione (GSH) are the most abundant small molecule biological thiols ( Figure 1 ). Owing to their characteristic redox properties and nucleophilicity,t hey play major unique roles in human health and disease.T hey were initially viewed primarily as antioxidants,p rotective agents serving as free radical scavengers.H owever,b ecause they maintain redox homeostasis through the equilibria between their reduced free thiol and oxidized disulfide forms, [1] monitoring the relative levels of reduced and oxidized thiols in cells became atraditional means of assessing oxidative stress.More recent investigations have prompted ar edefinition of oxidative stress based largely on changes in post-translational protein thiol modifications. [2] Because oxidative stress is amajor aspect of the development of many chronic and degenerative illnesses including cancer, autoimmune disorders,a ging, cataracts,r heumatoid arthritis, and cardiovascular and neurodegenerative diseases,monitoring the levels of biological thiols has as ignificant role in biomedical research and diagnostics. [3] Analytical methods typically involving separation steps have been used previously to address the detection and determination of specific biothiols.These have included highperformance liquid chromatography (HPLC), [4] capillary electrophoresis, [5] spectrophotometry, [6] voltammetry, [7] mass spectrometry (MS), [8] and HPLC-MS/MS. [9] Fluorometry has some specific advantages over these techniques such as speed, cost, and relative operational simplicity.HPLC-MS continues to serve as arguably the most useful of these approaches for diagnostics and certain research areas;h owever, ar elatively Biothiols such as cysteine (Cys), homocysteine (Hcy), and glutathione (GSH) play crucial roles in maintaining redox homeostasis in biological systems.T his Minireview summarizes the most significant current challenges in the field of thiol-reactive probes for biomedical researchand diagnostics,emphasizing the needs and opportunities that have been under-investigated by chemists in the selective probe and sensor field. Progress on multiple binding site probes to distinguish Cys,H cy,a nd GSH is highlighted as acreative new direction in the field that can enable simultaneous,a ccurate ratiometric monitoring. New probe design strategies and researcher priorities can better help address current challenges,i ncluding the monitoring of disease states such as autism and chronic diseases involving oxidative stress that are characterizedb ydivergent levels of GSH, Cys,and Hcy. [*] Prof. C. X. Yin, K. M. Xionglonger analysis time renders it sub-optimal for some researchers and, significantly,f or rapid point-of-care emergencyroom, bedside,o ri ntraoperative diagnostics.I ta lso is currently not optimal for home testing,doctorsoffice testing, or for developing-nation settings that lack water and electricity.Finally,itoften requires derivatization and, moreover, is relatively expensive compared to fluorescence-based sensor methods,r equiring individual run charges and high instrument-maintenance costs.
Alarge number of thiol-reactive reagents and probes have been commercially available for many years,filling an entire chapter of the Molecular Probes Handbook. [10] However,they are non-selective among the thiols,forming covalent adducts with any sulfhydryl-containing molecules.I ti si mportant to realize that such universal thiol-reactive probes are sometimes marketed or reported in the literature as GSH (or Cys)-selective.T here is an assumption that because GSH is the most abundant (1-10 mm levels) thiol in cells,a ny signaling from an interaction with Hcy or Cys (micromolar concentrations in cells) would be negligible.This may be true,though this assumption is typically reported without experimental evidence.H owever,i nh uman blood plasma, GSH (just 3-5 mm)isless abundant than Cys (10-20 mm)asunbound thiol, and an unaware probe end-user will encounter artificially high values attributed to GSH arising from Cys and Hcy.
Chemists in the sensor and supramolecular fields have been motivated to investigate aminothiol sensors not only due to their biomedical significance but also because of the fundamental challenges inherent in creating reagents that enable the selective detection of each of the specific thiols in natural media. Prior reviews have summarized biothiol fluorescent probes from different perspectives including bioimaging applications, [11] structure and reaction classification, [12] reaction types, [13] detection methods,a nd reaction mechanisms. [14] There have been al arge number of fluorescent probes for biothiols reported in just the past decade. Most can be divided into three categories based on function: 1) Thed etection of GSH/Cys/Hcy( universal thiol probes) over other amino acids, [15] 2) the selective detection one or two of GSH/Cys/Hcy (Table 1) , and 2) simultaneous discrimination of Cys,Hcy,and GSH. This purpose of this Minireview is two-fold. Thefirst is to focus on new probe design, such as multiple-binding-site fluorescent probes to concurrently distinguish Cys,H cy,a nd GSH. Thes econd is to highlight the most significant and most under-investigated challenges and applications relevant to selective thiol sensor and probe research.
In only afew cases of recent probe methods,investigations have led to an enhanced understanding of the fundamental redox chemistry of specific thiols. [16] Many studies to date have focused on the design of probes with optimized selectivity,s ignaling,a nd kinetics.H owever,m ost of the probes developed during the past decade have been limited to function in biological media as imaging agents in live cells,as shown in Table 1 An emerging trend, and the focus of this review,i st he design of multiple binding site sensors that not only enable excellent discrimination among the three main thiols but also allow for their simultaneous detection. However,there are,to date,relatively very few examples of such probes.T hese and related creative advances will allow researchers and clinicians [19] Fluorescein derivative [20] Hcy Human plasma CysH uman plasma Fluorescein derivative [21] SNF-probe [22] Cys + Hcy Human plasma Cys + Hcy HepG2 cells
Benzothiazole derivative [23] Coumarin derivative [24] GSH Human plasma CysH epG2 cells
Resorufin derivative [25] Chromene derivative [26] Cys + Hcy HepG2 cells GSH HeLa cells
FRET dyad [27] BODIPY derivative [28] GSH HeLa cells CysP C-12 cells BODIPY derivative [29] Fluorescein derivatives [30] GSH B16 cells GSH MCF-7cells
Pyronin dye [31] BODIPY dye [32] GSH HeLa cells GSH HeLa cells KC-Br [33] Coumarinyl aldehyde [8c] GSH Hep3B cells GSH Human renal cell carcinoma SiHa cells Phenyl-selenium [34] Coumarin-enone Dye [35] Cys + Hcy HepG2 cells CysH eLa cells NIR dye [36] 8-alkynyl BODIPY [37] Angewandte Chemie to address the most significant barriers to specific thiol monitoring,t hereby having ag reater impact on biomedical research. Moreover,m ultiple binding and signaling sites in thiol probes potentially will not only promote enhanced quantitative accuracy owing to analyte-specific ratiometric signals but will also serve as as tep towards more holistic single diagnostic reagents.F or example,s uch reagents could have ar ole in monitoring diseases with divergent relative levels of specific thiols,s uch as autism, wherein children present elevated levels of Hcy [17] but depleted levels of GSH and Cys. [18] 2. Significant Challenges in the Thiol-Probe Field.
There are critical unmet needs for improved probes to address current biomedical problems,particularly in the areas of GSH and Hcy monitoring.These include specific issues and applications that have generally not been addressed by chemists in the thiol probe and sensor field either at all or at least far short in proportion to their significance to human health.
Opportunities for GSH probe and sensor development
GSH is atripeptide possessing an internal Cys residue.It is produced in virtually all organs and is present in all tissues. It is the most abundant low-molecular weight biological thiol found in cells,a ppearing at millimolar levels (Cys and Hcy levels in cells are in the micromolar range). It is am ajor cellular antioxidant, reacting with reactive oxygen species (ROS) as well as free radicals.T he exchange of its sulfhydryl proton for afree radical located on biomolecules is the basis of the biological repair process.GSH is also involved in DNA synthesis,amino acid transport, and xenobiotic detoxification. [38] TPE-Py [39] Cys + GSH HeLa cells Cys + Hcy No study AHBO [40] Ruthenium complex [41] GSH
MKN-45 cells and HeLa cells GSH MKN-45 cells and HeLa cells
S-S-BODIPY-S [42] MeO-BODIPY-C [43] GSH + Hcy L929 cells Cys + Hcy HeLa cells TP3 [44] L 2 [45] GSH HepG2 cells Hcy HeLa cells
Rhodaminederivative [46] Pyrene derivative [47] CysH eLa cells Cys + GSH HeLa cells Chloro-hydroxyl merocyanine derivative [48] Chloro-dialkylamino-coumarin conjugated with malonitrile [49] It serves as an enzyme cofactor and substrate.I tregulates nitric oxide production. [50] In cells,the ratio of reduced (GSH, thiol form) to oxidized (GSSG,d isulfide form) is aw ellknown measure of oxidative stress as well as general cellular redox status.M ost GSH (> 90 %) is present in the reduced (GSH, sulfhydryl) form in cells. [51] GSH deficiencyisarisk factor for major chronic diseases including heart disease,s troke,c ancer, chronic respiratory diseases,a nd diabetes.C hronic diseases are characterized by long duration and relatively slow progression. Collectively, they cause over 60 %o fa ll deaths worldwide.G SH levels have been used to follow progression and treatment outcomes;h owever, the GSH levels reported suffer from poor inter-a nd intra-laboratory reproducibility.F or example, according to one author "it is evident that the measured concentrations…are highly divergent among different research groups…findings should be reconsidered once (there is) ag eneral agreement about the physiological levels…". [52] This issue of inconsistencyh as been attributed to the variability in analytical methods,the use of different matrices (plasma vs.b lood), sample oxidation, inconsistent sample preparations,a nd al ack of general standardized techniques. [53] Sample handling issues have been cited as main causes of the irreproducibility and variance in GSH determinations. [54] In addition, exacerbating these variance issues has been ambiguity in whether labs are reporting blood (which includes cellular millimolar levels of GSH) or plasma (micromolar ranges of GSH). There are also specific issues related to the available assays.Anumber of issues specific to GC-and HPLC-MS have been described. Ag old standard for GSH monitoring is the glutathione-S-transferase-catalyzedr eaction of monochlorobimane and GSH. However,t he monochlorobimane fluorogen is unstable at ambient temperature, under ambient light, and in water. Its byproducts are fluorescent and cause elevated readings.C ommercial GSH kits typically also feature relatively fragile materials and multistep procedures.Importantly,m ost are not selective for GSH over other thiols.C ys and DTT (dithiothreitol, the common thiol reducing agent) are common interferents. GSH-labeling kits such as ThiolTracker Violet, useful in GSH imaging,will react with other free thiols in addition to GSH.
Ther ange of GSH depletion associated with specific chronic diseases varies from 20 %to50%,with an average of more than 30 %. [55] Researchers have discovered that blood GSH testing led to earlier detection of asymptomatic patients with structural cardiac abnormalities,a sc ompared to an overexpression of soluble TNF receptor-1 (sTNFR1), aw ellknown biomarker of symptomatic heart failure severity that is also associated with oxidative stress.The patients in the study exhibited GSH decreases as high as 58 %. [56] Other examples of GSH depletion monitoring,e ach involving circa 20-50 %GSH decreases compared to healthy levels,i nclude:1 )Birth defects and complications during pregnancy, 2) side-effects of post-operative therapy,3 )endstage renal disease therapy,4)mitochondrial diseases,5)hospital sepsis,and 6) autism. Forexample,inbirth defects,GSH and Hcy levels tracked pre-eclampsia and normotensive pregnancies. [57] Whole-blood GSH measurements enabled the monitoring of patient responses to glutamine (GLN) therapy following open heart surgery. [58] Mitochondrial disease may be diagnosed based on cellular GSH levels. [59] Monitoring the restoration of depleted GSH levels has also been used in endstage renal disease. [60] In one review article it was stated that, despite the imprecision of current GSH assays,t he significance of GSH monitoring in hemodialysis patients is too significant to overlook.
[60a]
In summary,c urrent GSH assays have suffered from imprecision. This has had consequence in hindering progress in av ariety of serious issues.T he development of simple, rapid and reliable indicator-based methods enabling selective GSH detection, with limited or no sample handling,t hat are practical enough to achieve broad acceptance and standardization, will have asignificant, positive impact on the study and treatment of chronic disease.
Opportunities for Hcy probe and sensor development
Hyperhomocysteinemia (HHcy)isdefined as total plasma homocysteine (tHcy,t he sum of reduced free sulfhydryl and oxidized disulfide forms of Hcy) above circa 12-15 mm. Despite decades of research, Hcyr emains highly controversial. There is no general agreement on Hcysassociation with disease. [61] Extensive large scale clinical trials,i nvolving tens of thousands of patients,have failed to establish any definitive relationship between Hcyl owering and reduced cardiovascular disease (CVD) risk. This stunning dichotomy with the observational evidence that Hcy is linked to CVD and several other major disorders has rendered Hcysr ole in disease ahighly contentious topic. [61] Hcy is the one-carbon homologue of Cys.However, unlike Cys,H cy is typically incorporated into proteins post-translationally,e ither through disulfide bonds to Cys residues or amide bonds to Lysr esidues.H yperhomocysteinemia has been linked to numerous major pathologies including CVD, birth defects,o steoporosis,A lzheimersd isease,a nd renal failure,a mong many others.
Theterm total homocysteine (tHcy) is amisnomer.Inthe clinical protocols used to measure tHcy levels,atleast half of the Hcy forms (as its metabolites) are not accounted for. For example,Hcy-thiolactone (HTL) is found in all human cells,is more toxic than Hcy to human endothelial cells,a nd reacts readily with protein Lysr esidues affording N-Hcy-protein, anew protein thiol (Figure 2) . N-Hcy-protein levels were not accounted for in the clinical trials involving Hcy lowering. There is strong evidence that N-Hcy-protein is associated with coronary artery disease (CAD), induces cell death, causes autoimmune responses,a nd interferes with blood clotting. [62] Thep roteolytic degradation of N-Hcy-protein produces the isopeptide Ne-Hcy-Lys.Levels of N-Hcy-protein and Ne-HcyLysa re in the micromolar range in circulation, within the range of what has been termed tHcy. N e -Hcy-Lys is also (in alimited number of patients,however) apotential independent predictor of heart attack within 12 ho fc hest pain symptoms. [63] We have reported that N-Hcy-protein formation promotes free radical damage to proteins and protein carbonyl formation. [16] Angewandte Chemie HPLC can enable the monitoring of Hcy levels along with other structurally related analytes,s uch as Cys.H PLC methods have also been reported for determining levels of HTL [64] and N-Hcy-protein [65] as well as Ne-Hcy-Lys. [66] Hcy has been monitored by clinicians mainly by HPLC;however, it has not incorporated the simultaneous monitoring of the structurally related Hcy forms such as HTL, N-Hcy-protein, [65] and Ne-Hcy-Lys.Clinical monitoring is also relatively low throughput and involves al aborious sample pretreatment. HPLC is run sequentially,w ith each sample taking approximately 10-30 min. Immuno-and enzymatic assays can only monitor one analyte at atime.The Axis-Shield immunoassay method requires instruments that can handle multiple reagents per test and the relatively specialized fluorescent polarization (FP) detection. Thet ime required is approximately 30-45 min per test. Theprecision of the immunoassay is often lower than that of HPLC or enzymatic assays. Diazyme has created apromising commercial enzyme-cycling test for Hcyt hat is relatively faster, less expensive,a nd less labor intensive than HPLC and immunoassays.However,Hcy metabolites such as HTL (after ring opening), N-Hcy-protein, and N e -Hcy-Lys could, in principle,b em onitored by fluorescent probe methods analogous to those used for Hcy because they contain similar aminothiol structural elements. [16] Reagents that afford as elective optical response corresponding to Hcy as well as its metabolites,a samore global measure of Hcy,c ould facilitate basic research, clinical studies,a nd diagnostics in this field. It has been shown that selective-probe approaches can be rapid and can eliminate the need for sample preparation for the analysis of Hcyi n human samples. [67] Moreover,t hese methods have already shown promise for N-Hcy-protein determination. [16] Thef act that Hcy, Cys,a nd GSH can be discriminated by multiplebinding-site probes encourages optimism that analogous designs can enable simultaneous detection of Hcya nd its metabolites to facilitate elucidation of their interdependent roles in disease.O nt he other hand, there have been fewer reports of molecular sensors that are selective for Hcy,a s compared to those enabling Cys or GSH selectivity.Cys levels in plasma are typically 15-20-fold higher than those of Hcy. Therefore,t he selective detection of Hcy by abiotic chemosensors or dosimeters has been challenging,with some of the reports describing al ack of sensitivity at physiological thiol levels,f luorescence at only short wavelength excitation, or optimal function limited to non-aqueous solvents.
In summary,there is still aneed for Hcy-selective probes to facilitate the understanding of its role in disease as either ac ausative agent or as as pectator biomarker. TheH PLC methods are laborious.I na ny case,p ractical Hcyp robes, especially those enabling simultaneous or individual monitoring of HTL, N-Hcy-protein, and Ne-Hcy-Lys,a re more challenging and currently lacking compared to Cys and GSH probes. 
Angewandte
Chemie tuted aryl ring. Thet hiol derived from Cys undergoes rapid conjugate addition yielding highly fluorescent amino-coumarin 1-Cys.The reaction is slower in the case of the Hcyd erivative,p ossibly owing to al ess energetically-favorable 8-membered ring transition state.G SH forms 1-GSH, involving thiocoumarin formation and macrocyclization.
Probe 1 is virtually non-emissive at the excitation wavelength of 360 nm. Upon addition of Cys,anew emission peak appeared at 420 nm, taking 60 min to reach saturation. A53-fold increase in the fluorescence signal was observed. By comparison, at 420 nm Hcy and GSH only promoted 7-and 4-fold emission enhancements,r espectively,i ndicating the ability of probe 1 to discriminate Cys from Hcy/GSH. When 500 nm was selected as the excitation wavelength for detecting Hcy,o nly aw eak emission at 625 nm was observed that diminished upon Hcy addition. When l ex = 450 nm, upon addition of GSH an ew emission peak appeared at 512 nm. GSH produced a6 7-fold increase in fluorescence signal at the concentrations studied. When Cys,H cy,a nd Nacetylcysteine were added no change in the peak at 512 nm was observed. Overall, these results demonstrated that probe 1 enabled the highly selective detection of Cys and GSH from different emission channels (Figure 3) . [68] Moreover,p robe 1 was shown to enable the simultaneously imaging of Cys and GSH in COS-7 cells using different emission channels. Overall, this is ahighly promising result and avery interesting probe design. Much of the understanding of the probe properties and selective signaling was also derived from ac areful evaluation of the absorption spectra along with an analysis of intermediate reaction structures.A lthough the 60 min equilibration kinetics for Cys detection could be improved, and the signaling promoted by Hcy was suboptimal, this work embodies an excellent blueprint for the development of sensors for simultaneous GSH/Cys/Hcy detection.
Zhang et al. reported ac ommercial compound 2 (4F-2CN) as an efficient fluorescent probe with four potential reaction sites for detecting biological thiols (Figure 4) . [69] They hypothesized that the formation of 2-Cys was initiated by thiol substitution of afluoro group,followed by cyclization to displace as econd fluoro group.C onversely,t he formation of 2-Hcy (or 2-GSH) entailed substitution of two fluorine atoms by two equivalents of thiol. Probe 2 responded to Cys and emitted strong green fluorescence,w hereas it reacted with Hcy/GSHand generated blue fluorescence.T hus,probe 2 was capable of simultaneously detecting Cys and Hcy/GSH using dual emission channels.A ddition of CTAB (cetyl trimethylammonium bromide) was observed to alter the color of the reaction product of 2 and Hcy( from blue to green), but no alteration of the fluorescence color occurred for Cys and GSH. Furthermore,p robe 2 was used to image Cys/Hcy/GSH in HeLa cells.P otential drawbacks could be the long time (up to 2h)t or each an optimal signal and arelatively short wavelength excitation used in some experiments.H owever,t he researchers discovered that selective two-photon detection for Cys could be achieved upon excitation at 860 nm. This was ascribed to ac ombination of molecular rigidity and favorable electronic properties in the case of the Cys-probe adduct. Thes elective two-photon properties,c ombined with the clever use of CTAB,t he relative simplicity of the commercial probe,and the interplay between the thiol adduct structures and characteristic electronic properties,s hould enable analogous design strategies for optimal simultaneous analyte detection and imaging.
3.2. Condensation and reduction reactions for the discrimination of Cys, Hcy,a nd GSH Miao et al. reported sulfonamide-based self-quenched fluorescent probe 3 possessing two potential reaction sites for simultaneously sensing biothiols in physiological media with high sensitivity ( Figure 5) . [70] Thep robe reacted with GSH through sulfonamide cleavage to yield 3-GSH (CBT). When the probe reacted with Cys or Hcy,t he corresponding heterocycles formed. Each product exhibited different emission maxima (3-GSH, l em = 490 nm; 3-Hcy, l em = 517 nm; 3-Cys, l em = 522 nm). Furthermore, 3 was also successfully used for discriminating between Cys and GSH in HepG2 cells by ratiometric quantification.
Although fluorescence spectra needed to be acquired in buffer after 2h at 37 8 8Cu sing short wavelength (350 nm) excitation, the reactions of Hcya nd Cys with this probe are noteworthy alternatives to the formation of thiazinane and thiazolidine heterocycles that arise from aldehyde-functionalized fluorophores (examples shown in Table 1 ). Thed iffer- Liu et al. designed ac arboxylic acid-functionalized coumarin-hemicyanine fluorescent probe 4 with three potential reaction sites,at hioester group,acoumarin-hemicyanine unit, and abenzothiazolium Natom ( Figure 6 ). [71] Cys underwent an ative chemical ligation (NCL) reaction with 4 followed by cyclization to produce 4-Cys.H owever,t he reaction of 4 and Hcyr esulted in thioester 4-Hcy,w hich was stabilized by the electrostatic attraction between the carboxylate and heterocyclic benzothiazolium nitrogen. This stabilization was shown by molecular simulations to be more favorable for Hcyt han Cys,a nd thereby inhibited amide formation and subsequent cyclization. Similarly,inthe case of GSH, thioester probe 4-GSH was produced without amide formation owing to at en-membered ring transition state. They examined the emission behavior of 4 upon the addition of Cys,H cy,a nd GSH, by using two different excitations at 405 nm and 545 nm. Probe 4 displayed aw eak emission at 494 nm (l ex = 405 nm) and astrong emission at 644 nm (l ex = 545 nm). Upon the addition of Cys,t he emission intensity at 494 nm gradually increased with the simultaneous decrease in the emission at 644 nm. In this case,a na pproximate 96-fold enhancement of the ratiometric value (I 494 /I 644 )was observed.
However,the addition of Hcy(or GSH) induced only aslight change in the ratiometric value (1.6 and 0.78-fold for Hcy and GSH, respectively). Although, probe 4 could not achieve different signal responses,i tc ould engender distinctive reactivity among the biothiols.F urthermore,p robe 4 could be used to image Cys in the human renal cell carcinoma 786-0 cells.
Additionally,L iu et al. reported fluorescent probe 5 with two potential reaction sites ( Figure 7 ) to detect biothiols in pure PBS buffer. [72] Thep robe itself was non-fluorescent owing to the donor-excited photoinduced electron transfer (d-PET) process.T he Cys-induced Michael addition-rearrangement cascade reaction led to an amino-substituted product 5c with strong fluorescence.This was ascribed to inhibiting C=C isomerization-induced fluorescence quenching by an intramolecular N À H···O hydrogen bond. TheH cy (or GSH)-induced Michael addition reaction led to at hiol-substituted product 5b(or 5-GSH), which lacked asimilar intramolecular hydrogen-bonding interaction and thus displayed poor fluo- 
Chemie rescence due to efficient C=Cisomerization-induced fluorescence quenching. Even in the presence of Hcy (or GSH), the probe could detect Cys with obvious fluorescence enhancement. Although probe 5 failed to distinguish between all three of Cys,Hcy,and GSH, the but-3-yn-2-one group and the isomerization effects was effective for distinguishing between Cys and Hcy and embodies apotentially useful foundation for probes with even greater selectivity among the thiols.U sing al aser scanning confocal microscope,t he authors demonstrated that probe 5 could selectively image Cys in the human renal cell carcinoma 786-0 cells.
Nanoprobes as Materials for the Potential Discrimination of Cys, Hcy,a nd GSH
Although multiple-binding-site fluorescent probes can effectively distinguish Cys,H cy,a nd GSH, these fluorescent probes may suffer from complex synthesis routes.A dditionally,c hemical and photostability may be problematic and hinder practical applications.N anoparticle probes possess excellent photostability,good water solubility,chemical inertness,l ow toxicity,f avorable biocompatibility,a nd relatively low cost. [73] Targeted research on the use of quantum dots (QDs) [74] for bioanalytes of small molecular weight has been successful in the selective detection of biothiols over other amino acids without thiol groups.G uo et al. used N,S-carbon dots (N,SCDs) complexed with Cu II ,i nw hich the metal acts as the quencher,a nd the N,S-CDs fluorescence was reactivated by biothiols.T he N,S-CDs probe was successful in the selective detection of biothiols in human serum but so far lacks selectivity for each of GSH/Cys/Hcy.
[15t]
Then umber of nanoparticle probes that can selectively detect one or two of GSH/Cys/Hcyhas been increasing during the past decade. [75] However,n anoparticle probes that can simultaneously distinguish Cys,H cy,a nd GSH have not yet been reported. This is afertile area for further research since nanoparticles are amenable to functionalization with divergent receptors. [76] 
Summary and Outlook
In conclusion, multiple binding site probes can be used to not only distinguish the structurally related biothiols Cys,Hcy, and GSH but also enable their simultaneous monitoring, provided probe reactivity and specificity is optimal. This is significant because levels of each of the thiols are related to redox events associated with major diseases.T he use of multiple-binding-site probes is an ew and unique approach but is not the only strategy to address the issues facing modern thiol research. Future studies in this area can address critical issues in GSH and Hcym onitoring such as inter-laboratory inconsistencies and facilitate clinical trials.T he design principles for simultaneous thiol monitoring can also be applied to other significant targets such as the Hcym etabolites,t he perthiols,H 2 S, thiophenols,and many others.Moreover,there are many opportunities to create optimized probes based on the foundational principles described in the examples from the literature presented herein. Probes should be evaluated not only for their function in biological media such as cell culture and plasma for detecting one specific thiol but also should demonstrate clear selectivity in mixtures of thiols with dynamically changing levels of each analyte. [23] Future progress can enable the monitoring of disease progression and treatment by using multiple biomarkers in asimple,rapid and reliable manner. This will lead to more efficient clinical trials,d isease diagnostics and staging, and tracking of therapeutic outcomes and will help enhance the understanding of the chemical and biological basis of disease.
